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in both sporadic and hereditary TNBCs, and therapies targeting the 
BRCA1 pathway could have applications in sporadic TNBCs.
TNBC heterogeneity
TNBC is a diagnosis of exclusion defined by the lack of the 
ER, PR and HER2 biomarkers and this results in a high degree of 
heterogeneity. Given the poor outcome associated with TNBC as 
a whole, further stratification and tailored treatment options are 
required in order to improve the management of these patients.
Numerous studies have further sub-classified TNBC using 
varied techniques such as immunohistochemistry (IHC) and ‘omic’ 
strategies [7,8]. A number of clinically validated classification 
methods that were developed for breast cancer as a whole have been 
studied in the context of TNBC specifically. Application of the PAM50 
classifier (an intrinsic gene signature shown to classify tumours with 
clinically relevant subgroups) revealed that the majority (80%) of 
TNBCs are basal-like. The remaining tumours are classified as HER2 
enriched (10.2%), normal-like (4.6%), luminal B (3.5%) and luminal 
A (1.1%) [9]. Conversely, most, but not all, basal-like breast cancers 
(BLBC) are triple negative in nature [10] with up to 26% of these 
cancers being ER/PR positive or displaying amplification of HER2 
[9,11]. Application of the integrative clusters (IntClust) classifier 
(defined by a combination of copy number and gene expression data 
revealing 10 clusters of breast cancer), showed that BLBC contains a 
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Abstract
Triple Negative Breast Cancer (TNBC) is a highly heterogeneous disease. Lacking hormone receptors, ER and PR, as well as HER2 amplification, 
these cancers cannot be treated with more modern, targeted therapies such as tamoxifen or trastuzumab. Thus, the current standard of 
care for these patients is cytotoxic chemotherapy with varied clinical response. However, all patients experience unwanted and debilitating 
side effects regardless of response. Therefore, TNBC represents a significant unmet clinical need and finding more targeted and effective 
treatment approaches for this aggressive disease is an area of active research. The success of such agents has been hindered by the 
heterogeneity of the disease, with many new drugs only showing promising results in small populations. In order for targeted treatments 
to succeed, predictive biomarkers must be developed which can stratify patients and drive treatment choices. This review looks at the most 
promising areas of research regarding targeted therapy in TNBC as well as associated biomarkers that can be used to guide treatment.
Keywords: Triple negative breast cancer; Biomarkers; Personalised medicine; Targeted treatment
Introduction
The term triple negative breast cancer (TNBC) is used to describe 
a subset of breast cancers that are Estrogen Receptor (ER) negative, 
Progesterone Receptor (PR) negative and lack amplification of the 
Human Epidermal growth factor Receptor 2 (HER2) gene. Despite 
accounting for only approximately 15% of all breast cancers, TNBC 
accounts for a disproportionately high rate of mortality overall [1]. 
This is due to the aggressive and invasive nature of TNBC coupled 
with the lack of unique molecular targets available for directed 
therapy. Examples of such targeted treatments include anti-estrogens 
such as tamoxifen and anti-HER2 therapies such as trastuzumab 
(Herceptin®), which are used to treat ER- and HER2-positive breast 
cancer respectively [2]. Compared to other subtypes of breast cancer, 
TNBC has a propensity to disseminate to visceral organs such as the 
lungs or brain rather than bone [3]. Tumours are typically larger and 
more frequently lymph node positive [3,4], all of which indicates a 
unique biology. Rates of TNBC are higher in African American and 
Hispanic women and TNBC tends to occur in younger women [3,5]. 
Cancers arising from mutations in the breast and ovarian cancer 
tumour suppressor gene, BRCA1, also tend to be triple negative. 
Interestingly, a subset of sporadic TNBCs with wild type BRCA1 
share features associated with BRCA1 dysfunction, such as genomic 
instability and faults in DNA repair mechanisms. This phenomenon is 
known as “BRCAness” [6]. This indicates a potential role for BRCA1 
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heterogeneous distribution of these clusters, with IntClust 4 and 10 
representing over 80% [12]. IntClust 10 is defined by a high degree 
of genomic instability and chromosomal aberrations. Conversely, 
IntClust 4 is associated with a lack of copy-number variation, high 
immune infiltrate and an overall favourable outcome [13]. BLBC and 
TNBC are not synonymous but given the strong degree of overlap, the 
integrative clusters present in TNBC can be inferred from the analysis 
of basal-like tumours.
Further studies have developed TNBC specific classification 
methods. Lehmann BD, et al. [8,14] proposed 6 possible subgroups for 
TNBC based on Gene Expression (GE) profiles which was then further 
refined into 4 subgroups in a validation study (herein referred to as 
the Vanderbilt subtypes). These 4 subgroups consist of two basal-like 
subgroups (BL1, BL2), a Mesenchymal (M) and a Luminal Androgen 
Receptor subgroup (LAR). The gene signatures that identified 
the two previously included subgroups (immunomodulatory and 
mesenchymal stem-like) were determined to be from infiltrating 
lymphocytes and/or stromal cells rather than the tumour epithelial 
cells [8]. Apart from having distinct gene expression patterns, these 
subgroups displayed a range of clinical and histological differences 
(grade, stage and metastases) [8]. Furthermore, these subgroups do not 
respond uniformly to chemotherapy. The BL1 subgroup is associated 
with elevated cell cycle and DNA damage response gene expression and 
exhibited the highest response rates to chemotherapy (anthracycline/
cyclophosphamide/taxane based). Pathologic Complete Response 
(pCR-lack of residual disease in the breast and axillary lymph nodes 
after treatment) rates for this subgroup were 53%; higher than any 
other subgroup. The BL2 subgroup had characteristic growth factor 
signalling and myoepithelial markers. This subgroup had the poorest 
response to treatment, with a 0% pCR rate. The M subgroup, with a 
pCR rate of 31%, displayed elevated levels of genes responsible for 
epithelial-mesenchymal transition and growth factor signalling, with 
enrichment in pathways involved in cell motility and differentiation. 
The LAR subgroup was defined by high levels of androgen receptor 
gene signalling and luminal cytokeratin expression. The LAR subtype 
cancers responded poorly to chemotherapy with pCR rates of just 10% 
[15,16].
Other groups have attempted to classify TNBC into clinically 
relevant subtypes, however these analyses have not been validated and 
characterised to the same extent as the Vanderbilt subtypes. Burstein 
MD et al. [7] subtyped TNBC via DNA/RNA profiling. They identified 
four TNBC subtypes: LAR, Mesenchymal (MES), Basal-Like Immune 
Activated (BLIA) and Basal-Like Immune Suppressed (BLIS). Each 
subtype varied with respect to treatment targets and prognoses. A 
further study using gene expression to subtype TNBC divided tumours 
into three clusters: C1-LAR, C2-basal like with low immune response/
high M2-like macrophages (BLLIR), C3-basal like with high immune 
response/low M2-like macrophages (BLHIR) [17].
It is apparent that appropriate subtyping is the critical first step 
in order to identify biomarkers that can stratify patients in order to 
optimise treatment choices (Table 1). There appears to be a general 
trend among most studies of two basal-like subtypes, an androgen 
receptor expressing subtype, and a subtype associated with immune 
signalling. The reaching of a consensus on this issue will aid the 
identification of trends in this heterogeneous population and allow a 
more personalised approach to be used, ultimately leading to improved 
patient outcome.
Treatment of TNBC
Despite the poor overall prognosis and lack of molecular targets for 
treatment, patients with TNBC tend to have an overall higher response 
to chemotherapy than other cancers. This is known as the “TNBC 
paradox” [12,18]. This TNBC phenomenon may be explained by the 
fact that following chemotherapy, approximately two thirds of patients 
have favourable response and, when studied in the neoadjuvant setting, 
achieve a pCR [1,3]. These patients are classified as “good responders”. 
In contrast, the remaining patients (“poor responders”), present with 
cancers that are either intrinsically resistant to chemotherapy or rapidly 
develop resistance with residual disease post-treatment [3]. These 
patients have unfavourable outcomes and a high rate of recurrence. 
Typically, less than 30% of these patients will survive beyond 5 
years [12,14]. This can be attributed to the aggressive nature of 
TNBC and the lack of therapeutic alternatives to chemotherapy when 
treatment fails.
There also appears to be a strong time-dependent link between 
failure of chemotherapy and progression/death. Liedtke C et al. [1] 
showed that there is a significantly higher risk of progression and 
death in TNBC in the first 3 years following diagnosis, after which 
the risk falls and is comparable, if not lower than that of non-TNBC. 
Such trends are in stark contrast to non-TNBC cases which show an 
unchanging risk of relapse over time [1]. This illustrates how overall 
survival of TNBC is intrinsically linked to the response to first line 
treatment, with good responses leading to long term survival.
The TNBC paradox has led to many trials attempting to ascertain 
the optimal chemotherapy regimen for TNBC. The current generally 
accepted Standard of Care (SoC) for TNBC is an adjuvant regimen 
of cytotoxic chemotherapy, often containing anthracyclines, with 
the addition of taxanes in response to lymph node involvement. 
However, following a number of clinical trials and reviews there is 
now a shift towards the use of neoadjuvant regimens consisting of 
an alkylating agent plus anthracycline and taxane based agents. This 
has been extensively reviewed elsewhere and now forms the basis of 
the American Society of Clinical Oncology (ASCO) guidelines for 
the treatment of TNBC [19-22]. In addition to the improved patient 
outcomes, neoadjuvant treatment also allows clinicians to measure 
and assess response to chemotherapy more readily as tissue is available 
for analysis following resection [19,21]. Furthermore, this may be a 
suitable treatment strategy for patients who present with tumours that 
are inoperable. In addition to changes in the timing of treatment, the 
frequency/density of chemotherapy is also under investigation. Some 
studies have shown that the use of dose dense regimens of adjuvant 
chemotherapy in TNBC lead to improvements in Disease Free Survival 
(DFS) and Overall Survival (OS) [23,24].
While anthracyclines and taxanes have formed the backbone 
of chemotherapy to date, other agents have been investigated with 
promising results. These include platinum agents (discussed below) 
as well as capecitabine which was investigated in the CREATE-X trial 
for patients with HER2 negative disease displaying residual disease 
following neoadjuvant chemotherapy. The addition of capecitabine to 
SoC in these patients prolonged DFS and OS [25]. This may represent 
a treatment option for this poor outcome population.
In order to improve survival in TNBC as a whole, we must develop 
biomarkers to stratify patients and tailor treatment options accordingly. 
It would appear that the subset of TNBC patients who respond well 
to the current standard of chemotherapy should continue to receive 
such therapy. However, there is a dearth of alternative treatment 
options for the patients who do not respond. Several agents are under 
investigation in the clinical and pre-clinical setting with different 
targets and biomarkers designed to augment treatment (Table 2). This 
review is designed to interrogate emerging treatment strategies and 
biomarkers in TNBC in tandem with landmark clinical trials.
 Sci Forschen
O p e n  H U B  f o r  S c i e n t i f i c  R e s e a r c h
Citation: Elkashif A, McCarthy HO, Buckley NE (2018) Personalising the Fight against Triple Negative Breast Cancer. J Breast Cancer Res 
Adv 1(1): dx.doi.org/10.16966/jbcra.106 3
Journal of Breast Cancer Research and Advancements
Open Access Journal
PARP Inhibition
Poly (ADP-ribose) Polymerase (PARP) 1 is a nuclear enzyme that 
is involved in a number of cellular pathways leading to DNA repair 
and apoptosis. PARP catalyses the transfer of ADP-ribose to target 
proteins which activates the signalling mechanisms necessary for 
cell survival and is responsible for the repair of single strand breaks 
by Base Excision Repair (BER) [12]. Inhibition of PARP leads to the 
accumulation of single strand breaks that degenerate into double 
strand breaks in replicating cells [26]. Such breaks can be repaired 
through Homologous Recombination (HR). However, in cells that 
are deficient for BRCA1 and BRCA2, HR is impaired which results in 
an accumulation of unrepaired DNA damage and apoptosis ensues. 
This concept is known as synthetic lethality, meaning that inhibition 
of PARP will only lead to toxicity in cells which have impaired HR 
(i.e. tumour cells), while normal cells will be able to repair the DNA 
damage and survive [27,28].
PARP inhibitors, recently approved for the treatment of BRCA 
mutated breast and ovarian cancer [29,30], may also have a role to 
play in the treatment of TNBC given their association with BRCAness. 
As these tumours are thought to display Homologous Recombination 
Defects (HRD), they are predicted to be more susceptible to DNA 
damaging agents such as PARP inhibitors. In addition, inhibition of 
PARP upregulates cellular sensitivity to chemotherapy and ionising 
radiation [12,27].
Clinical trials have been conducted to investigate the safety and 
efficacy of PARP inhibitors in TNBC, both as monotherapy and in 
combination with other agents. Olaparib, an orally available PARP 
inhibitor has been implemented in BRCA associated breast cancer 
at high (400 mg twice daily) and low (100 mg twice daily) doses 
in the ICEBERG 1 trial (Including 29 TNBC patients out of the 51 
BRCA mutated cancers) with response rates ranging from 22% to 
41% and minimal toxicity [31]. The OlympiAD trial, a recent phase 
III clinical trial, assessed the use of olaparib as monotherapy versus 
SoC for BRCA mutated, HER2 negative Metastatic Breast Cancer 
(MBC) [32]. The primary endpoint for this trial was Progression Free 
Survival (PFS). 302 patients were recruited and assigned to receive 
either olaparib 300 mg twice daily (N=205) or standard care of the 
physician’s choice (N=97). The olaparib group had improved PFS (7 
months vs 4.2 months) and response rates (59.9% vs 28.8%). Olaparib 
monotherapy also led to reduced adverse events compared to standard 
care (eribulin, capecitabine, vinorelbine). The authors concluded that 
olaparib monotherapy was an effective treatment strategy for these 
patients. Olaparib has also been investigated in combination with 
weekly paclitaxel in patients with metastatic TNBC. Although some 
response was observed, this was associated with adverse effects such 
as neutropenia, diarrhoea and nausea [33]. Other studies have failed 
to show significant response rates to olaparib as a single agent in 
TNBC [34], suggesting more trials are needed in the TNBC setting to 
determine whether efficacy in BRCA mutated cancers can be translated 
to TNBC. Another PARP inhibitor, iniparib showed increased 
response rates, clinical benefit and PFS in a phase II trial, when used 
in combination with gemcitabine and carboplatin compared with 
gemcitabine and carboplatin alone [35]. This study however, failed 
to progress past phase III trials as the primary endpoints of clinical 
benefit and rate of stable disease were not met [36]. Studies involving 
iniparib have since been discontinued as it has failed to demonstrate 
adequate inhibition of PARP in in vitro studies [37]. Iniparib was 
shown to act through modulation of reactive oxygen species, rather 
than being a true PARP inhibitor and exhibited 1000-fold less activity 
than other PARP inhibitors [38]. Activity in previous clinical trials was 
attributed to non-selective interactions with various proteins. Other 
trials involving PARP inhibitors are ongoing and there are several new 
agents in clinical trials such as veliparib and talazoparib, estimated 
to be completed in 2019. [12,39]. EMBRACA is an ongoing clinical 
trial looking at talazoparib for the treatment of advanced breast cancer 
with a germline BRCA mutation [40]. Initial results suggest that 
talazoparib as monotherapy is potentially more effective than standard 
Drug Class/Target Example Drug (s) Associated Biomarker (s)
PARP Olaparib BRCA1/HRD
Platinum agents Cisplatin/Carboplatin HRD
AR Enzalutamide AR expression/LAR type TNBC
EGFR Cetuximab EGFR expression
VEGF Sunitinib VEGF1/2 expression
Tyrosine Kinase Inhibitors Dasatinib/Bosutinib C-kit, Src
PI3K/mTOR Everolimus/Temsirolimus LAR type TNBC
Immunotherapy Avelumab PL-L1/PD1, TIL
CDK4/6 Ribociclib/Palbociclib LAR type TNBC
Table 2: Summary of emerging treatment targets in TNBC along with associated drugs and biomarkers
Reference Cohort Method used Subtypes Comments
Lehmann [8, 14] N=587 Gene expression BL1, BL2, M, LAR (Formerly 
IM & MSL)
BL1 highest pCR rates & genomically 
unstable, BL2 lowest pCR rates
Burstein [7] N=84 (validated in 114) RNA/DNA Profiling LAR, MES, BLIA, BLIS BLIS worst prognosis, BLIA best prognosis
Jézéquel [17] N=107 (validated in N=87) Gene expression C1-LAR, C2-BLLIR, C3-
BLHIR 
C3 tumours have best outcome
Curtis [13]
N=997 (discovery), N=995 
(validation)
Gene expression/copy 
number analysis
IntClust 1-10 Clusters with distinct clinical outcomes, 
intrinsic subtypes split between clusters
Lehmann [10,105] N=374 Gene expression 
signature (PAM50)
Basal-like, HER2, Normal-
like, Luminal A, Luminal B
80% TNBCs basal-like when PAM50 
classifier is applied
Table 1: Subtyping studies on patient biopsies diagnosed with TNBC
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of care chemotherapy. The phase III trial BrighTNess has found that 
the addition of carboplatin to SoC neoadjuvant chemotherapy in 
TNBC improved pCR rates, however the addition of veliparib and 
carboplatin in combination added to toxicity with no improvement in 
efficacy [41]. Heterogeneity may account for the differing success rates 
of clinical trials involving PARP inhibitors. In an unstratified TNBC 
population, where only BRCAness patients are predicted to respond, 
sufficient numbers displaying this phenotype may not be present and 
this will inevitably lead to failure of clinical trials. Further trials that 
divide TNBC into sub-groups before treatment are critical to future 
successful clinical testing of these therapies.
This highlights the need for a biomarker for BRCAness. A number 
of assays are being developed/tested with this goal in mind. The 
BRAC Analysis® assay (Myriad Genetics Inc, Salt Lake City, USA) 
is an FDA approved test for BRCA 1/2 mutations in patient blood, 
used to inform choice for use of PARP inhibitors [42]. It detects 
variants in the protein coding regions of BRCA 1/2 genes and is 
used as a companion diagnostic alongside Lynparza® (Olaparib). 
Another assay currently in development from Myriad Genetics is 
the MyChoice® HRD assay, which is a DNA based assay that assigns 
a score based on tumour loss of heterozygosity, telomeric allelic 
imbalance and large scale state transitions [43]. Other approaches 
to this end include analysing gene expression signatures to assess 
BRCAness. One group has demonstrated that the use of a novel gene 
expression signature algorithm is more predictive of PARP inhibitor 
response than assessment of BRCA1/2 status in cancer cell lines. This 
algorithm identified patients with DNA repair deficiencies without 
BRCA1/2 mutations as well as those with mutations in BRCA1/2 that 
were resistant to PARP inhibition [44]. Such in vitro studies need to 
be clinically tested/validated before being used as treatment guides. 
Additionally, the DNA Damage Response Deficiency (DDRD) assay 
has been shown to be a statistically significant predictor of response 
to DNA damaging chemotherapy [45]. This gene microarray-based 
assay consisting of a 44 gene signature detects abnormalities in the 
Fanconi anaemia/BRCA/DDR pathway and has since been shown to 
be driven at a molecular level by the cGAS/STING pathway [46]. In 
one cohort studied, 32.5% of patients successfully predicted to achieve 
a pCR were BRCA1/2 wild type, demonstrating the DDRD assays 
ability to detect faults in DNA damage repair unrelated to BRCA1/2 
mutations [45]. The assays described have been proven to be useful 
tools guiding PARP inhibitor treatment in in vitro and/or retrospective 
analyses. The application of these assays in clinical trials and in routine 
practice could improve outcomes for patients who would otherwise go 
undetected, receiving ineffective treatments.
Platinum Agents
Carboplatin and cisplatin are bi-functional alkylating agents that 
intercalate in the DNA causing inter- and intra-strand breaks. TNBC 
represents a group of cancers that are predicted to be sensitive to such 
agents [47].
Silver DP, et al. [48] found that 22% of patients with TNBC, 
including both wild type and mutant BRCA1, treated with single 
agent cisplatin achieved a pCR, with 64% showing either a complete 
or partial response. The CALGB40603 trial demonstrated the addition 
of carboplatin to neoadjuvant chemotherapy increased pCR rates 
from 44% to 60% among 443 patients with stage II/III TNBC [49]. 
These results are promising but must be interpreted with caution as the 
addition of platinum agents in the adjuvant setting has not significantly 
impacted Relapse Free Survival (RFS) or OS in studies to date [50,51]. 
This may be due to the fact that such trials are carried out on unstratified 
TNBC populations with wide genetic and clinical heterogeneity. 
Significant end points cannot be reached unless the relevant treatment 
groups likely to benefit from treatment are identified and selected 
for during clinical studies. This has been demonstrated in the TNT 
trial which compared carboplatin vs docetaxel in TNBC, while taking 
into account BRCA1/2 status [52]. Patients with BRCA1/2 mutations 
treated with carboplatin had twice the Overall Response Rate (ORR) 
of those treated with docetaxel (33% vs. 68% respectively). In the 
unselected population, there was no significant difference between 
the two therapies, which demonstrates how selecting for a BRCAness 
population can increase the efficacy of platinum agents significantly. 
A systematic review of the use of platinum agents in TNBC by Poggio 
F, et al. [53] revealed that the addition of platinum agents to standard 
anthracycline/taxane based neoadjuvant chemotherapy significantly 
increased pCR rates in TNBC. Interestingly, they found that this effect 
was not limited to BRCA-mutated breast cancers, implying these 
agents could have clinical benefit for a larger proportion of TNBC 
patients.
The same biomarkers and assays used to measure BRCAness/DNA 
damage repair discussed previously could be applied in the context of 
platinum agents. As these drugs target cells with an inability to repair 
DNA, defects in the DNA damage response pathway or in homologous 
recombination could reveal tumours that are highly susceptible to 
them.
Androgen Receptor Targeting
Targeting of the Androgen Receptor (AR) has emerged as an 
intriguing approach to the treatment of TNBC. AR is a steroid 
hormone receptor responsible for sexual differentiation and 
reproductive development [54]. Binding of androgen to the receptor 
leads to translocation to the nucleus and activation of various 
transcription factors resulting in cellular proliferation and survival. 
A number of IHC-based studies have identified an AR positive 
subgroup of TNBC though the proportions vary based on antibodies 
and criteria used. For example, three different trials using a threshold 
of >10% nuclear expression found AR positive TNBC rates of 12%, 
38% and 66% respectively [55-57]. The Luminal Androgen Receptor 
(LAR) molecular subtype of TNBC described by Lehmann BD, et al. 
[8,14] accounts for 11% of TNBC and has the unique feature of having 
growth driven by, and dependent on, androgen receptor signalling. 
Furthermore, the LAR subtype responds poorly to conventional 
chemotherapy compared to other subtypes, with one of the lowest 
pCR rates-just 10% [15]. Despite the LAR subtype showing highest 
expression of AR, it has also been shown that expression of AR is also 
present in non-LAR subtypes of TNBC highlighting the varied results 
found when different classification methods are applied to TNBC 
[58,59].
Following the success in prostate cancer, several investigations into 
the efficacy and safety of androgen receptor targeting in the treatment 
of TNBC have proceeded into early phase clinical trials. A phase II 
trial using bicalutamide, a non-steroidal, orally available competitive 
inhibitor [55] showed that AR was expressed in 12% of TNBCs (51 
out of 424 patients) and the use of bicalutamide in these patients 
gave a Clinical Benefit Rate (CBR) of 19% and a median PFS of 12 
weeks. CBR was defined as the percentage of patients who achieved a 
complete response, partial response or who had stable disease after 6 
months. Bicalutamide was well tolerated with minimal adverse effects. 
This study also found that patients with AR positive TNBC tended to 
be older patients, with more soft tissue and bone metastases, which is 
atypical for TNBC [55].
Enzalutamide is another AR inhibitor that is currently approved 
in the treatment of prostate cancer. It acts by preventing the nuclear 
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translocation of the receptor, thus inhibiting DNA binding activity 
[60]. A phase II clinical trial looking at the use of enzalutamide in 
AR positive TNBC has shown promising results [57]. This study 
showed CBR rates of 25% at 16 weeks and 20% at 24 weeks in 78 AR 
positive patients, selected for from 118 TNBC cases. There were also 
2 complete responses and 5 partial responses. Enzalutamide was well 
tolerated in these patients, with only mild side effects reported such as 
nausea, fatigue and decreased appetite. Enzalutamide also increased 
OS (12.7 months to 17.6 months) and PFS (2.9 months to 3.3 months). 
Finally, a phase II, multi-centre clinical trial of abiraterone acetate, an 
orally available AR inhibitor, used in AR positive TNBC showed a 6 
month CBR of 20% with one patient showing a complete response 
and 5 patients showing stable disease [56]. 53 out of 138 (38%) TNBC 
patients were deemed to be AR positive, 30 of whom were evaluable 
for the primary endpoint of 25% CBR. Although this endpoint was 
not reached, these results are clinically relevant as they show that this 
treatment approach has some activity in the selected patient group. 
These studies collectively indicate that a group of patients within the 
umbrella term of TNBC would benefit from the use of AR antagonists 
in their treatment [54,61,62].
In addition to improving treatment choices, the prognostic 
capabilities of AR could extend to predicting disease progression 
and response to current SoC treatment. One study examined novel 
prognostic biomarkers in TNBC and noted the positive association 
between AR and DFS/OS [63]. This study also showed that the absence 
of AR was associated with higher histological grade and greater 
likelihood of metastasis. It is clear that the role of AR in TNBC should 
not be disregarded and warrants further interrogation for use as both 
a prognostic and predictive biomarker.
EGFR Inhibition
The Epidermal Growth Factor Receptor (EGFR) is emerging as 
a novel druggable target and prognostic biomarker in TNBC. This 
receptor is involved in stimulating cellular proliferation through 
multiple downstream pathways such as MAPK and AKT, and inhibition 
can be used to reduce tumour growth. EGFR has been shown to be 
over expressed in TNBC/BLBC compared to other subtypes, holding 
potential for use as a target [2,64,65]. Inhibitors of EGFR have been 
developed and are currently approved for the treatment of various 
conditions. Cetuximab is a chimeric monoclonal antibody that binds 
to, and inhibits EGFR, which is currently used in the treatment of 
colorectal cancer [66]. The small molecule tyrosine kinase inhibitors 
erlotinib and gefitinib are also currently approved for the treatment of 
a range of cancers including lung and pancreatic [64].
The efforts to find new, more targeted approaches to the treatment 
of TNBC have led to several clinical trials involving EGFR inhibitors 
both as a monotherapy and in addition to cytotoxic chemotherapy. A 
phase II clinical trial (TBCRC 001) by Carey LA, et al. [67] examined 
the use of cetuximab alone, or in combination with carboplatin in 
stage IV TNBC. Response rates (the primary endpoint) of patients 
in this trial were modest, at 6% (2 of 31) for cetuximab alone and 
16% in combination with cisplatin (4 of 25). This trial also failed to 
show a significant increase in PFS or OS. However, the combination 
of cisplatin and cetuximab vs cisplatin did double the ORR from 
10% to 20% in the combination arm and there was no significant 
increase in toxicity. While the primary endpoints in this study were 
not met, the use of EGFR inhibitors as an add-on therapy to cytotoxic 
chemotherapy does appear to show some clinical benefit. Additional 
studies have shown promise in the addition of EGFR inhibitors to 
conventional chemotherapies such as irinotecan and carboplatin 
[68]. The N0436 study, a phase II clinical trial, demonstrated the 
combination of cetuximab and irinotecan in MBC showed improved 
clinical benefit in the TNBC subgroup vs non-TNBC (response rate 
18% vs 0%) [69]. Erlotinib, a small molecule tyrosine kinase inhibitor 
that targets EGFR, was evaluated in combination with platinum/
taxane based chemotherapy using 2 regimens, leading to pCR rates of 
39% and 50% [70].
There can be no doubt that the selective treatment of patients with 
high EGFR levels may lead to improved response rates in clinical trials 
of EGFR-targeted agents. The expression of EGFR has also been shown 
to be associated with poor survival (log rank p=0.007), supporting 
its use as a prognostic biomarker [71]. EGFR expression has been 
shown to be associated with TNBCs that are more difficult to treat and 
correlates with significantly reduced 10-year survival rates [72]. Indeed, 
retrospective studies found that expression of EGFR leads to reduced 
DFS and OS in patients with TNBC [73,74]. A study in Japan has also 
revealed an increased EGFR copy number in TNBC compared to non-
TNBC [75]. EGFR expression correlates with aggressive features (>3 
lymph nodes, grade 3) [73] and patients expressing EGFR are unlikely 
to respond to chemotherapy [63]. These findings have the potential 
to impact current SoC for patients, and could facilitate a personalised 
approach to care, leading to treatment with optimal benefit.
VEGF Pathway Inhibition
TNBC is a highly proliferative cancer which relies on constant 
formation of new blood vessels for growth and survival. Therefore, the 
Vascular Endothelial Growth Factor (VEGF) pathway is important in 
the pathophysiology of TNBC. Signalling from the VEGF receptor is 
essential in the formation of new blood vessels (angiogenesis) as well 
as invasion of tumours and increased vascular permeability [76]. This 
increase in vascular density triggered by VEGF signalling gives rise to 
more aggressive tumours in breast cancer [77].
Monoclonal antibodies targeted against VEGF or tyrosine 
kinase inhibitors, which prevent phosphorylation associated with 
downstream signalling have been developed. Bevacizumab is a 
humanised monoclonal antibody that specifically binds to, and 
inhibits, VEGF-A and associated isoforms [26]. It is currently licensed 
for ocular conditions such as age-related macular degeneration and 
colorectal cancer. Several clinical trials have investigated the use 
of bevacizumab in MBC and specifically in TNBC. A number of 
these clinical trials have focussed on the addition of bevacizumab 
to currently approved chemotherapeutic regimens such as taxanes 
or anthracycline-based therapies with improvements in PFS and OS 
noted [78-82]. For example, the RAD001 clinical trial examined the 
use of bevacizumab in addition to epirubicin, cyclophosphamide 
and docetaxel and determined a significant increase in the rates 
of pCR among 663 patients with TNBC from 27.9% to 39.3% [83]. 
This response did not occur in the non-TNBC group demonstrating 
specificity for VEGF targeting in TNBC. In the CALGB 40603 trial, 
the addition of bevacizumab to a regimen consisting of paclitaxel, 
doxorubicin and cyclophosphamide showed an increase in pCR rates 
from 48% to 59% [49]. VEGF levels have also been used to predict 
response to VEGF-targeted therapy with high VEGF serum levels 
found to be predictive of good response to bevacizumab in TNBC [84].
Sunitinib is an orally available multitargeted tyrosine kinase 
inhibitor that inhibits VEGF as well as Platelet-Derived Growth 
Factor Receptor (PDGFR), c-Kit and colony-stimulating factor 1 
receptor (CSF-1R) [85]. A phase II, multi-centre study of sunitinib 
monotherapy in MBC showed moderate activity in cancers pre-
treated with anthracyclines, with a response rate of 15% in TNBC [86]. 
However, a follow up phase III trial has not demonstrated the use of 
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sunitinib to be beneficial [87]. Two clinical trials (SOLTI-0701 and 
RESILIENCE) involving sorafenib, another tyrosine kinase inhibitor 
that inhibits VEGF signalling, have shown modest activity in HER2 
negative MBC [88-90], though patients were not further stratified 
based on expression of ER or PR. The combination of VEGF inhibitors 
with bevacizumab and sorafenib has also been assessed among 18 
patients (8 with TNBC) in the BRE06-109 trial [91]. This combination 
was deemed too toxic for further study and the trial was terminated. 
Results of further clinical trials will confirm whether there is a role for 
such agents in the treatment of MBC and TNBC.
Several investigations have revealed that the expression of VEGF 
in TNBC is significantly higher than in non-TNBC (54.3% vs 
22.9%) [76,92,93]. It has also been shown that VEGFR expression 
is higher in metastatic breast cancer than in non-metastatic breast 
cancer by approximately twofold [94,95]. These findings potentially 
implicate VEGF involvement in the more aggressive and invasive 
disease progression associated with TNBC. Significant links have 
been established between VEGF expression and DFS/OS with high 
expression associated with worse outcomes [77,93]. VEGF2 has also 
been found to be a significant prognostic biomarker for TNBC with 
high expression of VEGF2 associated with decreased 5 and 10 year 
survival rates in a cohort of 96 TNBC patients selected from a total 
of 564 [96,97]. This indicates the potential for VEGF and associated 
receptors to be used both to inform prognosis and guide targeted 
therapy.
Multi-Tyrosine Kinase Inhibitors
Interest in multiple tyrosine kinase inhibitors has grown in 
recent times as the effort to find targeted treatments for TNBC 
continues. Tyrosine kinases are enzymes that are involved in the 
phosphorylation of various proteins, usually as part of a downstream 
signalling pathway. These include the Src kinases, a family of non-
receptor tyrosine kinases responsible for cellular proliferation and 
differentiation [98]. Abnormal activity of Src kinases impacts growth, 
angiogenesis and migration of breast tumours [99,100]. Furthermore, 
Src was found to be expressed in the majority of TNBC tumours 
(95%) and more frequently than in non-TNBC tumours (84%) [98]. 
Dasatinib is a potent, orally available inhibitor of multiple tyrosine 
kinases such as Src, Bcr-Abl, PDGFR and c-Kit, currently approved for 
use in leukaemia [98,101]. A number of studies have looked at using 
dasatinib as monotherapy or in combination for the treatment of MBC 
and TNBC. Despite promising results in pre-clinical studies, dasatinib 
has failed to show benefit in clinical trials as a single agent in TNBC 
with ORR of just 4.7%, and in MBC (0% PFS at 16 weeks) [99,100]. 
Although single agent activity of dasatinib is limited, it appears to 
show potential in combination with other agents. The combination 
of dasatinib with cetuximab and cisplatin had a synergistic effect of 
growth inhibition in TNBC cell lines compared to either alone [102]. 
A phase I clinical trial investigated the combination of paclitaxel and 
dasatinib in 15 MBC cases, 6 of which were TNBC. The combination 
demonstrated preliminary activity, with 4 out of 13 assessable patients 
having a partial response and an additional 5 displaying stable disease 
[101]. Bosutinib, a Src/Abl tyrosine kinase inhibitor has been evaluated 
as a single agent in MBC in a phase II clinical trial [103]. 16-week PFS 
rates for these patients were 39.6% in the overall population and 25% 
in the TNBC subset. Despite the lower PFS rates in TNBC, the findings 
from this trial indicate that bosutinib showed promising antitumour 
activity and may warrant further investigation.
PI3K/mTOR Pathway Targeting
The PI3K/mTOR pathway is a signalling pathway responsible 
for cell growth, survival and cell cycle regulation [104]. Abnormal 
activation of this pathway has been implicated in many types of breast 
cancer [8] and mutations of PI3K have been found in 10-21% of 
TNBCs [105,106]. Lehmann BD et al. [105] found that mutations in 
this pathway are potential drivers of growth in the LAR subtype of 
TNBC, with activating mutations present in all LAR cell lines analysed. 
In vitro studies have shown that the growth of LAR-type cell lines is 
inhibited by dual PI3K/mTOR inhibition [8]. mTOR is an effector of 
this pathway and mutations are frequently found to increase its activity 
leading to uncontrolled cell growth [26]. Abnormal functioning of 
this pathway can occur by activating mutations of PI3K itself, or from 
mutations in negative regulators of the pathway, such as PTEN [107]. 
Pre-clinical studies have shown that dysregulation of the PI3K/mTOR 
pathway sensitises cancer cells to mTOR inhibitors [88]. Additionally, 
it has been found that inhibitors of PI3K may lead to DNA damage 
and down regulation of BRCA1/2 [107]. This disrupts the process of 
homologous repair and stabilises double strand breaks in DNA. This 
finding has led to studies of PI3K inhibitors alongside DNA damaging 
chemotherapy as a new approach to treating TNBC. Results of these 
in vitro studies indicate that PI3K inhibition sensitises TNBC to PARP 
inhibition [107] and suggests investigation in a clinical trial setting is 
warranted.
Everolimus and temsirolimus are orally available inhibitors of 
mTOR that are currently approved for the treatment of renal cancer 
[104]. Trials of everolimus in TNBC have been conflicting. Everolimus 
alongside weekly cisplatin and paclitaxel in HER2 negative MBC 
caused significant anti-tumour activity at a range of doses in a phase 
II trial of 55 patients, of which 63% were TNBC [108]. A phase II trial 
in 25 TNBC patients treated with everolimus and carboplatin revealed 
a CBR of 36%, with 1 complete response, 6 partial responses and 7 
patients with stable disease [109]. Another phase II trial assessing the 
addition of everolimus to a regimen of paclitaxel/FEC (5-fluorouracil, 
epirubicin, cyclophosphamide) saw the combination therapy giving 
rise to higher pCR rates (25.9% vs 30.4%) and was well tolerated [110]. 
The addition of temsirolimus or everolimus to liposomal doxorubicin 
and bevacizumab was also beneficial, with improvements in ORR 
[111]. In contrast, two recent phase II trials found that the addition 
of everolimus to chemotherapy (paclitaxel/cisplatin, gemcitabine/
cisplatin respectively) caused no increase in efficacy, but did add 
to toxicity [112,113]. Further clinical trials, with emphasis on the 
subtypes of TNBC treated, will ascertain whether this treatment 
approach is beneficial.
Immunotherapy
Immunotherapy is a rapidly evolving area and there is significant 
research involving the development of new targeted treatments and 
biomarkers in TNBC. The immune system plays a key role in all 
cancers and immunotherapy has been used successfully in a range of 
tumours. Evidence that the immune system plays an important role in 
disease progression and survival in breast cancer is abundant, given 
findings that infiltrates of CD8+ T cells are associated with improved 
outcomes in breast cancer [114], and specifically basal-like breast 
cancer [115]. Conversely, the presence of CD4+ T cells is linked to 
poor outcomes. Various TNBC sub typing studies have also identified 
a population characterised by high levels of immune infiltrate [7,8,17]. 
This suggests that an immunotherapeutic approach to treatment 
would be beneficial, at least for this group.
Several candidates for immunotherapy have been put forward 
and such agents are currently undergoing clinical and pre-clinical 
studies [116-118]. Studies in this area have thus far been limited to 
advanced disease, but as these trials progress, if efficacy is proven 
they have the potential to be studied in the early disease setting. One 
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immunotherapeutic marker of interest is PD-L1, which upon binding 
to its receptor (PD-1) acts as an immune checkpoint receptor to down 
regulate T cell functioning [119]. PD-L1 has been found to be highly 
expressed in 20% of an unstratified TNBC population (N=105) and 
is present in higher levels than non-TNBC [120]. Pembrolizumab is 
a humanised monoclonal antibody that binds to PD-1, blocking its 
activation by its ligand PD-L1 [119]. The KEYNOTE-012 phase IIb 
clinical trial evaluated pembrolizumab as a single agent in patients 
with advanced TNBC with assessment for PD-L1 status [121]. PD-L1 
status was assessed by IHC, and positivity was confirmed by stromal 
expression or >1% tumour expression. Of 111 TNBC patients initially 
assessed, 58.6% were PD-L1 positive. 32 patients were enrolled for 
treatment, with an ORR of 18.5% after treatment. This study led to 
the KEYNOTE-086 trial, which assessed pembrolizumab in pre-
treated TNBC cases, regardless of PD-L1 status [122]. The ORR in 
this group was 5%, with the treatment regimen showing a good safety 
profile. The KEYNOTE trials show how stratifying patients based on 
the biology of their specific cancers can lead to targeted therapy that is 
more effective. It is likely that there is significant overlap between the 
immune rich TNBC subtype identified by gene expression studies, 
and the patients that display PD-L1 expression in the tumour 
tissue. Durvalumab is an IgG1 monoclonal antibody which blocks 
PD1/PD-L1 binding, and has been implicated in lung, bladder and 
other cancers [123,124]. The combination of durvalumab and the 
PARP inhibitor olaparib has been investigated in a range of cancers 
including BRCA1/2 mutant, HER2 negative breast cancers in the 
MEDIOLA trial [125]. Initial results show the combination of drugs 
is tolerable and displays preliminary efficacy in this patient group, 
with further study warranted [126]. There are ongoing clinical trials 
assessing this pathway as a target for immunotherapy in TNBC [127] 
and significant efforts to determine the optimal predictive biomarker 
for response.
Tumour vaccines have also gained interest and are being evaluated 
in the context of TNBC. These treatments aim to stimulate the host 
immune system to fight and destroy cancer cells. Tumour vaccines 
have the potential to be used as preventative treatment as well as 
therapeutically. They can contain cancer cells or antigens to evoke 
a host immune response. One such cancer antigen is MUC1, a cell 
surface based mucoprotein that is abnormally expressed or glycosylated 
in various cancers, including TNBC [128,129]. The combination of 
a MUC1 vaccine with a monoclonal antibody inhibiting cytotoxic 
T-lymphocyte associated protein 4 (CTLA-4) thereby acting as an 
immune checkpoint blocker was found to have significant in vivo 
anti-tumour activity in TNBC [130]. Another antigen of interest is 
NY-ESO-1, which was shown to be expressed in 16% of 168 TNBC 
cases in one study, with 78% of these patients showing an antibody 
response to the antigen [131]. This high immunogenicity makes 
NY-ESO-1 a promising candidate for the development of a tumour 
vaccine. This is a relatively novel area of research and investigations 
are continuing into new immunotherapeutic compounds and 
approaches to treat TNBC.
Immune markers also have significant prognostic value in TNBC. 
Key observations have shown that the presence of Tumour Invading 
Lymphocytes (TILs) is associated with improved survival and improved 
response to anthracycline based chemotherapy [128,132,133]. 
Additionally, as discussed previously, immune markers can be used 
to identify patients that will respond to various treatments, be it 
immunotherapy or other chemotherapies. Further clinical trials 
which take into account expression of immune markers such 
as PD-L1, may yield more significant results in stratified TNBC 
populations.
CDK4/6 Inhibition
Targeting of Cyclin Dependent Kinases (CDK) has recently 
emerged as a novel way of treating a variety of cancers; owing to their 
important roles in the cell cycle [134]. CDKs are enzymes that interact 
with cyclin subunits to phosphorylate proteins. In doing this, they can 
act as cell cycle regulators, ensuring progression through the cell cycle, 
as well as regulating processes such as transcription and apoptosis 
[135]. CDK4/6 interacts with cyclin D subunits to phosphorylate 
the Retinoblastoma protein (RB). RB is a tumour suppressor protein 
that negatively regulates the cell cycle. Phosphorylation of RB causes 
inactivation, allowing cell progression through the cell cycle. It has 
been shown that the loss of RB is more common in TNBC than in other 
breast cancer subtypes [136] and disruption of the normal function 
of CDK4/6 occurs in breast and other cancers [137]. The resulting 
unregulated cell cycle allows cells to divide uncontrollably. In this way, 
aberrant CDK4/6 function can drive oncogenesis and pharmacological 
inhibition of this has been investigated in over 20 types of cancers 
[137]. One of these agents, palbociclib (a highly selective CDK4/6 
inhibitor) is currently approved in the treatment of ER positive breast 
cancer [135]. Trials of CDK4/6 inhibition in the context of TNBC have 
not yet reached the clinical setting but interest in this area is growing. 
Two recent studies have found that TNBC cell lines are sensitive to 
treatment with palbociclib and that this effect is synergistic when 
combined with PI3K inhibitors [138,139]. This combination of therapy 
increased cancer cell toxicity and immunogenicity. Although such 
studies are in their early stages, inhibition of CDK4/6 could present a 
novel and effective means of treating a subset of TNBC.
Conclusion
In summary, TNBC is a highly heterogeneous disease and 
treatment options based on a single disease result in limitations for 
clinical benefit and development of novel agents. There is a wide range 
of promising treatment approaches being investigated for TNBC. 
Many of these are highly efficacious when used in the correct patient 
populations. This review highlights both single gene and multigene 
signatures that must be applied to clinical practice to identify relevant 
treatment groups in order to allow the development of novel therapies 
to progress. Stratification before treatment enables a personalised 
medicine approach that will improve survival and management of 
TNBC.
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